Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH

Open source

DOI: 10.1200/jco.2012.42.7906
Published: 2013 Jan 1
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.2012.42.7906,
  title = {Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.},
  author = {Advani RH and Buggy JJ and Sharman JP and Smith SM and Boyd TE and Grant B and Kolibaba KS and Furman RR and Rodriguez S and Chang BY and Sukbuntherng J and Izumi R and Hamdy A and Hedrick E and Fowler NH},
  year = {2013},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco.2012.42.7906},
  url = {https://doi.org/10.1200/jco.2012.42.7906}
}

RIS

TY  - JOUR
TI  - Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
AU  - Advani RH
AU  - Buggy JJ
AU  - Sharman JP
AU  - Smith SM
AU  - Boyd TE
AU  - Grant B
AU  - Kolibaba KS
AU  - Furman RR
AU  - Rodriguez S
AU  - Chang BY
AU  - Sukbuntherng J
AU  - Izumi R
AU  - Hamdy A
AU  - Hedrick E
AU  - Fowler NH
PY  - 2013
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco.2012.42.7906
UR  - https://doi.org/10.1200/jco.2012.42.7906
ER  -

APA

RH, A., JJ, B., JP, S., SM, S., TE, B., B, G., KS, K., RR, F., S, R., BY, C., J, S., R, I., A, H., E, H., & NH, F. (2013). Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco.2012.42.7906

Source records

pubmed · retrieved 2026-09-25T08:03:37.865Z